SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
Status: Recruiting
Location: See location...
Intervention Type: Combination product
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This trial aims to evaluate the safety and efficiency of SBRT followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• Laryngeal (T3-4N0-3M0 ) and hypopharyngeal ( T2-4N0-3M0) cancers staged by AJCC8th
• age 18-70
• PS score 0-1
• normal functions to tolerate chemotherapy, immunotherapy and radiotherapy
Locations
Other Locations
China
Sun Yat-sen University Cancer Center
RECRUITING
Guangzhou
Contact Information
Primary
Fang-Yun Xie
xiefy@sysucc.org.cn
+8613902205880
Backup
Dian OuYang
ouyd@sysucc.org.cn
Time Frame
Start Date: 2024-09-11
Estimated Completion Date: 2027-09-11
Participants
Target number of participants: 35
Treatments
Experimental: SBRT+Toripalimab Plus Docetaxel and Cisplatin
SBRT for gross tumor and metastatic lymph nodes, followed by neoadjuvant chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin
Related Therapeutic Areas
Sponsors
Leads: Sun Yat-sen University